BLOG CATEGORY: Defective & Dangerous Drugs - Page 2

News & Commentary

Recall Of Generic Vicodin: FDA Announces Recall Over Concerns Of Overdose

Recall Of Generic Vicodin: FDA Announces Recall Over Concerns Of Overdose

In the wake of the news of recalls and poor production methods and conditions out of Ranbaxy Laboratories in India, the U.S. Food and Drug Administration has announced the recall of another popular generic medication over concerns that it could lead to overdose. The medication in question is a generic form of Vicodin produced by Qualitest, which is a subsidiary of Endo Health Solutions, according to a report by the FDA.

As it is, Vicodin is a combination of acetaminophen and hydrocodone, and it is prescribed by physicians and medical providers for treating severe pain. Because it is also an opioid-based painkiller and the body becomes accustomed to the pain relief that it provides, Vicodin and its related generic forms can be an addictive medication, which increases the chances of overdose as the body builds a stronger tolerance to the drug. In the case of this recall, that danger is even greater because the Qualitest pills potentially contain higher levels of acetaminophen and/or hydrocodone.

This recall has now been expanded from one initial lot of pills to 101 lots of hydrocodone bitartrate and acetaminophen tablets, USP 10 mg/500 mg. If patients are taking these specific pills, unaware of the higher ingredient levels, the results could be severely dangerous, with liver toxicity and dysfunction as extreme possibilities. According to the FDA:

“Taking a higher dose of hydrocodone than intended could result in an increase in the severity or frequency of side effects, such as sedation or respiratory depression, particularly in patients who are elderly, have severe kidney or liver impairment, or are also taking interacting medications, for example other sedating medications or certain antidepressants.”

The lots included in this recall were distributed by Qualitest between Feb. 20 and Nov. 19 this year, and the FDA is urging patients who may be using this generic form of Vicodin to stop using the drug immediately and contact Qualitest immediately at (800) 444-4011.

 

 

 

Generic Lipitor Recall Announced by Ranbaxy Laboratories Due To Impurities

Generic Lipitor Recall Announced by Ranbaxy Laboratories Due To Impurities

With global sales of more than $1 billion annually, Ranbaxy Laboratories is one of the biggest names in the collection of pharmaceutical companies that international giant Daiichi Sankyo has gathered over the past decade. Founded and operating in India, Ranbaxy has made its name as a developer of off-patent prescription medication, meaning that it produces and sells generic versions of popular drugs after the original manufacturers’ patents have expired. Most recently, in 2011, Ranbaxy was granted approval by the U.S.

Read more

Meningitis Outbreak: Second Pharmaceutical Company Shut Down In Wake of 28 Meningitis Fatalities

Meningitis Outbreak: Second Pharmaceutical Company Shut Down In Wake of 28 Meningitis Fatalities

For the past month, health clinics and medical care centers in 23 states have been dealing with contaminated steroid injections that have lead to a fungal meningitis outbreak. To date, 28 people have died as a result of these injections that had been used by physicians and health care providers in treating back pain, and there have been at least 363 additional non-fatal cases of illness reported in 23 states.

Read more

FDA Announces Removal of Generic Wellbutrin XL 300 mg

FDA Announces Removal of Generic Wellbutrin XL 300 mg

Part of the process of achieving Food and Drug Administration approval for prescription medication is the clinical trial. During a clinical trial, the drug will be tested multiple times to determine whether it works and if it has any side effects. To determine this information, the drug is tested against a placebo so accurate comparisons can be made, and a placebo, of course, is simply nothing more than an inert pill. But it’s important to realize that while placebos are meant to do absolutely nothing, prescription drugs are actually supposed to do something.

Read more

Actos Link To Bladder Cancer Leads To Decrease In Manufacturer’s Profits

Actos Link To Bladder Cancer Leads To Decrease In Manufacturer’s Profits

Amid recent warnings from the FDA and the public’s mounting worry over evidence that Actos (pioglitazone) may cause bladder cancer, Takeda Pharmaceutical Company is suffering a significant dent in its profits due to falling sales of the once popular diabetic drug.

Takeda Pharmaceutical Company, the biggest maker of drugs in Japan, has stated that it experienced net profits of only $1.74 billion for the six months before the end of September. The pharmaceutical company further states that it will have had a 31 percent decrease in its profit margin by March 2012.

Read more

Actos Multidistrict Litigation Pending As EMA And FDA Still Pushing Drug As Second Line Treatment

Actos Multidistrict Litigation Pending As EMA And FDA Still Pushing Drug As Second Line Treatment

The European Medicines Agency has recently announced that, despite a serious risk for causing bladder cancer, the prescription medication Actos – or Glustin as it is known in some European countries – should still be prescribed by physicians as a second or third line treatment option for patients suffering from Type 2 diabetes. The EMA – as well as the U.S. Food and Drug Administration – contended as recently as July 2011 that Actos createded a greater risk of bladder cancer to patients using the drugs than those not using them.

Read more

Takeda Attorneys Agree With Plaintiff Claim To Consolidate Actos Lawsuits

Takeda Attorneys Agree With Plaintiff Claim To Consolidate Actos Lawsuits

Back in August, plaintiffs suing the drug maker Takeda Pharmaceuticals filed motions to consolidate the lawsuits of bladder cancer patients who have taken Takeda’s drug Actos. On September 29, Takeda attorneys filed a response to the U.S. Judicial Panel on Multidistrict Litigation agreeing with the plaintiffs that multidistrict litigation, or MDL, should be formed to consolidate all pre-trial litigation in these cases.

Read more
x
OVER $500,000,000 recovered
Newsome Melton has recovered over half a billion dollars for their clients.
Product Liability Lawyer - Newsome Melton

    Please do not navigate away from this page until you receive a success notification.
    Product Liability Lawyer - Newsome Melton